<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005599</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067712</org_study_id>
    <secondary_id>MSKCC-99094</secondary_id>
    <secondary_id>MSKCC-FDR001826</secondary_id>
    <secondary_id>NCI-250</secondary_id>
    <nct_id>NCT00005599</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer</brief_title>
  <official_title>Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 and paclitaxel in treating&#xD;
      patients who have locally advanced or metastatic esophageal cancer or stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the complete and partial response rates in patients with unresectable or&#xD;
           metastatic esophageal cancer or carcinoma of the gastroesophageal junction treated with&#xD;
           sequential paclitaxel and bryostatin 1.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in this patient population.&#xD;
&#xD;
        -  Determine the survival of patients after treatment with this regimen.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Examine pre- and post-treatment tissue biopsies for markers of apoptosis in selected&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive paclitaxel IV over 1 hour on day 1 and bryostatin 1 IV over 24 hours on day&#xD;
      2 weekly for 2 weeks. Courses repeat every 28 days in the absence of unacceptable toxicity or&#xD;
      disease progression.&#xD;
&#xD;
      Quality of life is assessed at baseline, after courses 1 and 2, and then after every 2&#xD;
      courses thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-33 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or&#xD;
             carcinoma of the gastroesophageal (GE) junction&#xD;
&#xD;
               -  If tumor extends below GE junction into the proximal stomach, 50% of the tumor&#xD;
                  must involve the esophagus or GE junction&#xD;
&#xD;
               -  No gastric cancer with only a minor involvement of GE junction or distal&#xD;
                  esophagus&#xD;
&#xD;
          -  Locally advanced and considered surgically unresectable or metastatic&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Accurately measured in at least 1 dimension as at least 20 mm with conventional&#xD;
                  techniques or at least 10 mm with spiral CT scan&#xD;
&#xD;
               -  No truly nonmeasurable lesions only:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusions&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 150,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of active angina&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No history of significant ventricular arrhythmia requiring medication with&#xD;
             antiarrhythmics&#xD;
&#xD;
          -  Well-controlled atrial fibrillation on standard management allowed&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 60%&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 2 months after study&#xD;
             participation&#xD;
&#xD;
          -  No preexisting neurotoxicity of grade 3 or greater&#xD;
&#xD;
          -  No serious concurrent infection or nonmalignant medical illness that is uncontrolled&#xD;
             or whose control may be jeopardized by complications of study therapy&#xD;
&#xD;
          -  No concurrent psychiatric disorders that would preclude study compliance&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except:&#xD;
&#xD;
               -  Nonmelanoma skin cancer&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  History of T1a or b prostate cancer (detected incidentally at transurethral&#xD;
                  resection of prostate [TURP] and comprising less than 5% of resected tissue)&#xD;
                  provided prostate-specific antigen remained normal since TURP removal&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent medical condition that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No more than 1 prior neoadjuvant or adjuvant regimen for esophageal cancer&#xD;
&#xD;
          -  No prior taxanes for esophageal cancer&#xD;
&#xD;
          -  No prior bryostatin 1 for esophageal cancer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy allowed provided recent evidence of disease progression if&#xD;
             indicator lesion is within prior radiation field&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary K. Schwartz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Clinical Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ku GY, Ilson DH, Schwartz LH, Capanu M, O'Reilly E, Shah MA, Kelsen DP, Schwartz GK. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008 Oct;62(5):875-80. doi: 10.1007/s00280-008-0677-y. Epub 2008 Feb 13.</citation>
    <PMID>18270704</PMID>
  </results_reference>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

